TNO155 is an oral capsule that contains batoprotafib, an experimental medicine being studied to block signals that help cancer cells grow and survive. Participants take it by mouth as part of the trial.

Erbitux is a solution for infusion that contains cetuximab, a lab‑made antibody that attaches to a protein called EGFR on the surface of some cancer cells. By binding to EGFR, it can slow the growth of those cells. It is given through an IV line.

JDQ443 (opnurasib) is an oral tablet of an investigational drug that targets a specific mutation in cancer cells, helping to stop them from multiplying. In this rollover study, participants continue to take it alone or together with other treatments.

VDT482 is a concentrate for infusion that contains tislelizumab, a monoclonal antibody that helps the body’s immune system find and destroy cancer cells. It is administered through an IV infusion.

KRAS G12C‑mutated non‑small cell lung cancer – This is a type of lung cancer that begins in the cells lining the airways and carries a specific KRAS gene change called G12C. The mutation can make cancer cells grow more quickly. In locally advanced stages, the tumor spreads to nearby structures such as lymph nodes or the chest wall. In metastatic stages, cancer cells travel through the bloodstream to distant organs like the brain, liver, or bones. As the disease progresses, the tumor usually becomes larger and may cause symptoms such as cough, shortness of breath, or chest pain.

KRAS G12C‑mutated solid tumor – This term describes any solid cancer, such as those of the colon, pancreas, or other organs, that contains the KRAS G12C gene alteration. The mutation can drive uncontrolled cell growth. Over time the tumor may increase in size and invade surrounding tissues. It can also spread to other parts of the body, forming new tumor sites. The disease often moves from a localized stage to a more widespread stage as it advances.